Beta Bionics

Beta Bionics is a commercial-stage private company that has developed the iLet Bionic Pancreas, a differentiated automated insulin delivery system. The iLet's key differentiator is its algorithm, which requires only a user's body weight to initialize and then autonomously learns and adapts insulin delivery, eliminating the need for manual carb counting and dose calculations. The system is integrated with leading CGM sensors from Dexcom and Abbott and represents a significant step towards a fully autonomous, decision-free management solution for type 1 diabetes.

The iLet Bionic Pancreas System, an automated insulin delivery platform featuring a proprietary adaptive learning algorithm that autonomously determines all insulin micro-corrections and meal boluses based on CGM data, requiring only body weight for initialization and meal size announcements (not carb counts).

Beta Bionics competes in the automated insulin delivery market against major players like Medtronic (MiniMed 780G), Insulet (Omnipod 5), and Tandem Diabetes Care (t:slim X2 with Control-IQ). Its key differentiation is its algorithm that eliminates manual carb counting and dose calculations, aiming for greater simplicity and reduced user burden compared to systems that require more user input.